Medicaid Expansion and Utilization of Antihyperglycemic Therapies.
Andrew SumarsonoLeo F BuckleySara R MachadoRishi K WadheraHaider J WarraichRishi J DesaiBrendan M EverettDarren K McGuireGregg C FonarowJaved ButlerAmbarish PandeyMuthiah VaduganathanPublished in: Diabetes care (2020)
Use of noninsulin antihyperglycemic therapies, including SGLT2i and GLP-1RA, increased among low-income adults in both Medicaid expansion and nonexpansion states, with a significantly greater increase in overall use and in GLP-1RA use in expansion states. Future evaluation of the population-level health impact of expanded access to these therapies is needed.